Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

被引：14
|
作者：
Sekhar R.V. [1 ]
Jahoor F. [1 ]
Pownall H.J. [1 ]
Ballantyne C.M. [1 ]
Balasubramanyam A. [1 ]
机构：
[1] Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Insulin Resistance; Cholesteryl Ester Transfer Protein; Lipodystrophy; Postprandial Lipemia; Intramyocellular Lipid;
D O I：
10.1007/s11883-004-0029-2
中图分类号：
学科分类号：
摘要：
The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：173 / 179
页数：6
相关论文
共 50 条
  • [1] HIV-ASSOCIATED LIPODYSTROPHY AND EXERCISE
    Mutimura, E.
    Stewart, A.
    Crowther, N. J.
    [J]. SOUTH AFRICAN JOURNAL OF PHYSIOTHERAPY, 2006, 62 (02) : 2 - 4
  • [2] The HIV-associated lipodystrophy syndrome
    Mauss, S
    Schmutz, G
    [J]. MEDIZINISCHE KLINIK, 2001, 96 (07): : 391 - 401
  • [3] HIV-associated lipodystrophy syndrome
    Qaqish, RB
    Fisher, E
    Rublein, J
    Wohl, DA
    [J]. PHARMACOTHERAPY, 2000, 20 (01): : 13 - 22
  • [4] HIV-associated lipodystrophy syndrome
    Milinkovic, Ana
    [J]. COLLEGIUM ANTROPOLOGICUM, 2006, 30 : 59 - 62
  • [5] HIV-associated lipodystrophy syndrome
    Mauss, S
    [J]. AIDS, 2000, 14 : S197 - S207
  • [6] Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study
    Sekhar, Rajagopal V.
    Patel, Sanjeet G.
    D'Amico, Susana
    Shi, Jianjian
    Balasubramanyam, Ashok
    Rehman, Khaleel
    Jahoor, Farook
    Visnegarwala, Fehmida
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (06): : 754 - 760
  • [7] Experience in the treatment of HIV-associated lipodystrophy
    Nelson, L.
    Stewart, K. J.
    [J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2008, 61 (04): : 366 - 371
  • [8] Clinical management of HIV-associated lipodystrophy
    Pirmohamed, Munir
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (04) : 309 - 314
  • [9] Spotlight on Tesamorelin in HIV-Associated Lipodystrophy
    Sohita Dhillon
    [J]. BioDrugs, 2011, 25 : 405 - 408
  • [10] Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1363): : 34 - 35
12345